Project Grant R01CA306078
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $633K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
- The National Cancer Institute awarded Yale University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training in basic, clinical, and prevention research relevant to the National Cancer Program. The project, titled "Regulation of Protein Synthesis by PUS1-Mediated mRNA Modification in Hepatocellular Carcinoma," runs through December 31, 2028, with place of performance in New Haven, Connecticut. The research examines how...
- The National Institutes of Health National Cancer Institute awarded Sanford Burnham Prebys Medical Discovery Institute $803,681 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the functions of the nucleoporin NUP210 in leukemia. The funded research investigates how NUP210, a tissue-specific nucleoporin highly upregulated in aggressive myeloid leukemias and a predictor of poor patient survival, promotes leukemogenesis. Preliminary data indicate that...
- The National Institutes of Health National Cancer Institute awarded Beckman Research Institute of the City of Hope $2,486,215 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing R01CA313241) to conduct mutational epidemiology research on childhood acute lymphoblastic leukemia in California. The research combines tumor mutation pattern analysis with epidemiological methods to identify environmental causes of childhood ALL. The project leverages the...
- The National Cancer Institute awarded the University of California, Los Angeles $540,204 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small molecule modulators targeting the RNA exonuclease polynucleotide phosphorylase (PNPASE) as a therapeutic strategy for therapy-resistant, immune-cold KRAS/LKB1 mutant non-small cell lung cancer. The award funds research into PNPASE inhibitors (MTPNPIs) that induce accumulation of cytosolic mitochondrial...
- The National Cancer Institute awarded The Washington University Office of Sponsored Research Services $643,286 on August 1, 2026, to investigate DNA methylation epimutations in acute myeloid leukemia under the Cancer Biology Research program (CFDA 93.396). The research investigates allele-specific DNA methylation epimutations as clonal events that arise in normal cells and may be selected for during leukemogenesis. The project uses primary human acute myeloid leukemia samples, normal...
- The National Cancer Institute awarded Northwestern University $593,307 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying nucleophosmin 1 (NPM1)-driven acute myeloid leukemia leukemogenesis. The funded research examines how NPM1 cytoplasmic mutations (NPM1c), which occur in approximately 30 percent of adult de novo AML cases, cooperate with clonal hematopoiesis mutations in DNMT3A, TET2, or IDH1/2 to promote leukemic...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded the University of Illinois $422,649 as a Project Grant (R21CA303745) on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds research into racial disparities in acute myeloid leukemia (AML) treatment outcomes. The study examines whether NPM1 mutant status determines FOXM1 cytoplasmic localization and inactivation in primary bone marrow samples from Black AML...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded The Jackson Laboratory $543,984 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of ZBTB7A in acute myeloid leukemia differentiation through in vivo animal studies. The award funds animal model research using NSG-SGM3 mice to evaluate AML engraftment, disease progression, and therapeutic response in ways that cannot be...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $479,234 on May 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate nonsense-mediated mRNA decay mechanisms in cancer biology. The project explores how nonsense-mediated mRNA decay (NMD) functions beyond its conventional role of degrading faulty transcripts, with three specific aims: decode gene dependencies in cancer cell lines using NMD residual signatures from...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $501,422 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to advance synthetic lethal cancer therapeutics targeting the PELO-HBS1L ribosome rescue complex in cancers bearing biallelic chromosome 9P21.3 deletion or microsatellite instability mutations. The research validates whether super killer complex deficiency serves as a cancer-lineage agnostic predictor of PELO-HBS1L...